Skip to main content
CABA
NASDAQ Life Sciences

Rese-cel Holds Immunomodulator-Free Responses at One Year Across Three Autoimmune Diseases

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.34
Mkt Cap
$220.409M
52W Low
$1.18
52W High
$4.23
52W Position info
14% above low
Off High info
68% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CABA is trading near its 52-week low of $1.18 (14% above the low).

Summary

Cabaletta presented new Phase 1/2 rese-cel data at ACR Convergence 2026 showing durable, immunomodulator-free responses across dermatomyositis, lupus nephritis and systemic sclerosis. All 6 of 6 dermatomyositis patients held moderate-to-major TIS responses through one year, with 5 of 6 reaching that level by Week 16 — the timepoint that maps to the primary endpoint of the ongoing registrational DM/ASyS cohort. All 5 biopsied lupus nephritis patients achieved DORIS remission off immunomodulators with histologic response or remission, and 5 of 7 systemic sclerosis patients hit rCRISS-50 at one year with a 9% mean FVC improvement in the five ILD patients. Safety across 71 patients was clean: 94% had no or Grade 1 CRS, 96% had no ICANS, and no IEC-HS was reported. The data support the registrational path but do not change near-term timing — topline DM/ASyS results are guided to the second half of 2027 and the myositis BLA to the first quarter of 2028. This lands three days after the Q3 update that showed $299.4M in cash and removed the going-concern warning, so financing risk is off the table while the clinical readout remains the real driver.

At the time of this announcement, CABA was trading at $1.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.4M. The 52-week trading range was $1.18 to $4.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CABA - Latest Insights

CABA
Nov 05, 2026, 7:34 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $1.34 info
Change: -$0.1404 (-9%) info
Market Cap: $220.409M info
CABA
Nov 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $1.34 info
Change: -$0.1404 (-9%) info
Market Cap: $220.409M info
CABA
Sep 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $1.34 info
Change: -$1.43 (-52%) info
Market Cap: $220.409M info
CABA
Aug 13, 2026, 7:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $1.34 info
Change: -$1.48 (-52%) info
Market Cap: $220.409M info
CABA
Aug 13, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $1.34 info
Change: -$1.48 (-52%) info
Market Cap: $220.409M info